Patel Vihang, Pattisapu Anil, Attia Karim, Weiss John
Mount Carmel Health System, Columbus, Ohio, USA.
Case Rep Gastroenterol. 2017 May 22;11(2):344-347. doi: 10.1159/000468510. eCollection 2017 May-Aug.
Nilotinib, a second-generation tyrosine kinase inhibitor, is used for treatment of chronic myeloid leukemia (CML); it has been widely used especially for imatinib-resistant CML. Despite being a novel drug in this therapeutic class, it has the potential to be harmful. We present the case of an elderly woman who developed life-threatening acute pancreatitis as an adverse event after having started the drug. There is only one reported case in the literature of nilotinib-induced acute pancreatitis. The purpose of this case report is to educate physicians who prescribe this medication to be aware of potential life-threatening adverse events. As more and more therapies are available, physicians should be aware of potential effects of cancer treatment that could be life-threatening to patients.
尼洛替尼是一种第二代酪氨酸激酶抑制剂，用于治疗慢性髓性白血病（CML）；它已被广泛使用，尤其是用于对伊马替尼耐药的CML。尽管它是该治疗类别中的一种新药，但仍有潜在危害。我们报告了一例老年女性病例，该患者在开始使用该药物后发生了危及生命的急性胰腺炎这一不良事件。文献中仅报道了一例尼洛替尼诱发急性胰腺炎的病例。本病例报告的目的是教育开具此药的医生，使其意识到潜在的危及生命的不良事件。随着越来越多的治疗方法出现，医生应意识到癌症治疗可能对患者产生的危及生命的潜在影响。
